Early Changes in Alpha-Fetoprotein and Des-γ-Carboxy Prothrombin Are Useful Predictors of Antitumor Response to Durvalumab Plus Tremelimumab Therapy for Advanced Hepatocellular Carcinoma
Abstract
:1. Introduction
2. Materials and Methods
2.1. Patients
2.2. Dur/Tre Treatment, Evaluation of Adverse Events, and Changes in Liver Function
2.3. Determination of Antitumor Response
2.4. Evaluation of Changes in AFP, DCP, and AFP-L3
2.5. Statistical Analysis
3. Results
3.1. Patient Characteristics at Baseline
3.2. Antitumor Response at 8 Weeks after Dur/Tre Initiation According to RECIST 1.1 and mRECIST
3.3. PFS and OS by 8W-RECIST 1.1
3.4. AFP Ratios at 2, 4, and 8 Weeks after Dur/Tre Initiation, Stratified by 8W-RECIST 1.1
3.5. DCP Ratios at 2, 4, and 8 Weeks after Dur/Tre Initiation, Stratified by 8W-RECIST 1.1
3.6. AFP-L3 Ratios at 4 and 8 Weeks after Dur/Tre Initiation, Stratified by 8W-RECIST 1.1
3.7. Prognostic Factors at Start of Dur/Tre Associated with Good PFS
3.8. PFS by Treatment Line and NLR
3.9. Safety and Changes in Liver Function
3.10. Post-Progression Therapy
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Abou-Alfa, G.K.; Lau, G.; Kudo, M.; Chan, S.L.; Kelley, R.K.; Furuse, J.; Sukeepaisarnjaroen, W.; Kang, Y.K.; Dao, T.V.; De Toni, E.N.; et al. Tremelimumab plus durvalumab in unresected hepatocellular carcinoma. N. Eng. J. Med. Evid. 2022, 1, EVIDoa2100070. [Google Scholar]
- Reig, M.; Forner, A.; Rimola, J.; Ferrer-Fàbrega, J.; Burrel, M.; Garcia-Criado, Á.; Kelley, R.K.; Galle, P.R.; Mazzaferro, V.; Salem, R.; et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J. Hepatol. 2022, 76, 681–693. [Google Scholar] [CrossRef] [PubMed]
- Gordan, J.D.; Kennedy, E.B.; Abou-Alfa, G.K.; Beal, E.; Finn, R.S.; Gade, T.P.; Goff, L.; Gupta, S.; Guy, J.; Hoang, H.T.; et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update. J. Clin. Oncol. 2024, 42, 1830–1850. [Google Scholar] [CrossRef] [PubMed]
- Yeo, Y.H.; Lee, Y.T.; Tseng, H.R.; Zhu, Y.; You, S.; Agopian, V.G.; Yang, J.D. Alpha-fetoprotein: Past, present, and future. Hepatol. Commun. 2024, 8, e0422. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Toyoda, H.; Kumada, T.; Tada, T.; Sone, Y.; Kaneoka, Y.; Maeda, A. Tumor markers for hepatocellular carcinoma: Simple and significant predictors of outcome in patients with HCC. Liver Cancer 2015, 4, 126–136. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Kuzuya, T.; Asahina, Y.; Tsuchiya, K.; Tanaka, K.; Suzuki, Y.; Hoshioka, T.; Tamaki, S.; Kato, T.; Yasui, Y.; Hosokawa, T.; et al. Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma. Oncology 2011, 81, 251–258. [Google Scholar] [CrossRef] [PubMed]
- Kuzuya, T.; Ishigami, M.; Ishizu, Y.; Honda, T.; Hayashi, K.; Katano, Y.; Hirooka, Y.; Ishikawa, T.; Nakano, I.; Goto, H. Early clinical response after 2 weeks of sorafenib therapy predicts outcomes and anti-tumor response in patients with advanced hepatocellular carcinoma. PLoS ONE 2015, 10, e0138776. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Sánchez, A.I.P.; Roces, L.V.; García, I.Z.; López, E.L.; Hernandez, M.A.C.; Parejo, M.I.B.; Peña-Díaz, J. Value of α-fetoprotein as an early biomarker for treatment response to sorafenib therapy in advanced hepatocellular carcinoma. Oncol. Lett. 2018, 15, 8863–8870. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Kuzuya, T.; Ishigami, M.; Ito, T.; Ishizu, Y.; Honda, T.; Ishikawa, T.; Fujishiro, M. Favorable radiological antitumor response at 2 weeks after starting lenvatinib for patients with advanced hepatocellular carcinoma. Hepatol. Res. 2020, 50, 374–381. [Google Scholar] [CrossRef] [PubMed]
- Kodama, K.; Kawaoka, T.; Namba, M.; Uchikawa, S.; Ohya, K.; Morio, K.; Nakahara, T.; Murakami, E.; Yamauchi, M.; Hiramatsu, A.; et al. Correlation between early tumor marker response and imaging response in patients with advanced hepatocellular carcinoma treated with lenvatinib. Oncology 2019, 97, 75–81. [Google Scholar] [CrossRef] [PubMed]
- Saeki, I.; Yamasaki, T.; Yamashita, S.; Hanazono, T.; Urata, Y.; Furutani, T.; Yokoyama, Y.; Oishi, T.; Maeda, M.; Kimura, T.; et al. Early predictors of objective response in patients with hepatocellular carcinoma undergoing lenvatinib treatment. Cancers 2020, 12, 779. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Kuzuya, T.; Kawabe, N.; Hashimoto, S.; Miyahara, R.; Sawaki, A.; Nakano, T.; Nakaoka, K.; Tanaka, H.; Miyachi, Y.; Mii, A.; et al. Early changes in alpha-fetoprotein are a useful predictor of efficacy of atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma. Oncology 2022, 100, 12–21. [Google Scholar] [CrossRef] [PubMed]
- Tanaka, K.; Tsuji, K.; Hiraoka, A.; Tada, T.; Hirooka, M.; Kariyama, K.; Tani, J.; Atsukawa, M.; Takaguchi, K.; Itobayashi, E.; et al. Usefulness of tumor marker score for predicting the prognosis of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A multicenter retrospective study. Cancers 2023, 15, 4348. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Kinami, T.; Amioka, K.; Kawaoka, T.; Uchikawa, S.; Yamasaki, S.; Kosaka, M.; Johira, Y.; Yano, S.; Naruto, K.; Ando, Y.; et al. Evaluation of response to atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma using the combination of response evaluation criteria in solid tumors and alpha-fetoprotein. Cancers 2023, 15, 2304. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Campani, C.; Bamba-Funck, J.; Campion, B.; Sidali, S.; Blaise, L.; Ganne-Carrié, N.; Demory, A.; Sutter, O.; Larrey, E.; Evain, M.; et al. Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab-bevacizumab. Liver Int. 2023, 43, 708–717. [Google Scholar] [CrossRef] [PubMed]
- National Institutes of Health, National Cancer Institute, U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Published 27 November 2017. Available online: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf (accessed on 20 June 2020).
- Johnson, P.J.; Berhane, S.; Kagebayashi, C.; Satomura, S.; Teng, M.; Reeves, H.L.; O’Beirne, J.; Fox, R.; Skowronska, A.; Palmer, D.; et al. Assessment of liver function in patients with hepatocellular carcinoma: A new evidence-based approach—The ALBI grade. J. Clin. Oncol. 2015, 33, 550–558. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Eisenhauer, E.A.; Therasse, P.; Bogaerts, J.; Schwartz, L.H.; Sargent, D.; Ford, R.; Dancey, J.; Arbuck, S.; Gwyther, S.; Mooney, M.; et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer 2009, 45, 228–247. [Google Scholar] [CrossRef] [PubMed]
- Lencioni, R.; Llovet, J.M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin. Liver Dis. 2010, 30, 52–60. [Google Scholar] [CrossRef] [PubMed]
- Kanda, Y. Investigation of the freely available easy-to-use software E‘ZR’ for medical statistics. Bone Marrow Transpl. 2013, 48, 452–458. [Google Scholar] [CrossRef] [PubMed]
- Sangro, B.; Chan, S.L.; Kelley, R.K.; Lau, G.; Kudo, M.; Sukeepaisarnjaroen, W.; Yarchoan, M.; De Toni, E.N.; Furuse, J.; Kang, Y.K.; et al. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Ann. Oncol. 2024, 35, 448–457. [Google Scholar] [CrossRef] [PubMed]
- Ueshima, K.; Kudo, M.; Takita, M.; Nagai, T.; Tatsumi, C.; Ueda, T.; Kitai, S.; Ishikawa, E.; Yada, N.; Inoue, T.; et al. Des-γ-carboxyprothrombin may be a promising biomarker to determine the therapeutic efficacy of sorafenib for hepatocellular carcinoma. Dig. Dis. 2011, 29, 321–325. [Google Scholar] [CrossRef] [PubMed]
- Murata, K.; Suzuki, H.; Okano, H.; Oyamada, T.; Yasuda, Y.; Sakamoto, A. Cytoskeletal changes during epithelial-to-fibroblastoid conversion as a crucial mechanism of des-gamma-carboxy prothrombin production in hepatocellular carcinoma. Int. J. Oncol. 2009, 35, 1005–1014. [Google Scholar] [CrossRef] [PubMed]
- Norman, J.S.; Li, P.J.; Kotwani, P.; Shui, A.M.; Yao, F.; Mehta, N. AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation. J. Hepatol. 2023, 79, 1469–1477. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Halazun, K.J.; Rosenblatt, R.E.; Mehta, N.; Lai, Q.; Hajifathalian, K.; Gorgen, A.; Brar, G.; Sasaki, K.; Doyle, M.B.M.; Tabrizian, P.; et al. Dynamic α-Fetoprotein Response and Outcomes After Liver Transplant for Hepatocellular Carcinoma. JAMA Surg. 2021, 156, 559–567. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Singal, A.G.; Tayob, N.; Mehta, A.; Marrero, J.A.; El-Serag, H.; Jin, Q.; Saenz de Viteri, C.; Fobar, A.; Parikh, N.D. GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis. Hepatology 2022, 75, 541–549. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Wang, K.; Dong, L.; Lu, Q.; Yang, Z.; Fan, X.; Gao, F.; Ge, W.; Wang, Z.; Zhou, Z.; Lu, D.; et al. Incorporation of protein induced by vitamin K absence or antagonist-II into transplant criteria expands beneficiaries of liver transplantation for hepatocellular carcinoma: A multicenter retrospective cohort study in China. Int. J. Surg. 2023, 109, 4135–4144. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Eso, Y.; Takeda, H.; Taura, K.; Takai, A.; Takahashi, K.; Seno, H. Pretreatment neutrophil-to-lymphocyte ratio as a predictive marker of response to atezolizumab plus bevacizumab for hepatocellular carcinoma. Curr. Oncol. 2021, 28, 4157–4166. [Google Scholar] [CrossRef] [PubMed]
- Wang, J.H.; Chen, Y.Y.; Kee, K.M.; Wang, C.C.; Tsai, M.C.; Kuo, Y.H.; Hung, C.H.; Li, W.F.; Lai, H.L.; Chen, Y.H. The prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab. Cancers 2022, 14, 343. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Tada, T.; Kumada, T.; Hiraoka, A.; Hirooka, M.; Kariyama, K.; Tani, J.; Atsukawa, M.; Takaguchi, K.; Itobayashi, E.; Fukunishi, S.; et al. Neutrophil-lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A multicenter analysis. Eur. J. Gastroenterol. Hepatol. 2022, 34, 698–706. [Google Scholar] [CrossRef] [PubMed]
- Ochi, H.; Kurosaki, M.; Joko, K.; Mashiba, T.; Tamaki, N.; Tsuchiya, K.; Marusawa, H.; Tada, T.; Nakamura, S.; Narita, R.; et al. Usefulness of neutrophil-to-lymphocyte ratio in predicting progression and survival outcomes after atezolizumab-bevacizumab treatment for hepatocellular carcinoma. Hepatol. Res. 2023, 53, 61–71. [Google Scholar] [CrossRef] [PubMed]
- Takenaka, Y.; Oya, R.; Takemoto, N.; Inohara, H. Neutrophil-to-lymphocyte ratio as a prognostic marker for head and neck squamous cell carcinoma treated with immune checkpoint inhibitors: Meta-analysis. Head Neck 2022, 44, 1237–1245. [Google Scholar] [CrossRef] [PubMed]
- Wang, H.; Yang, R.; Liu, D.; Li, W. Association of pretreatment neutrophil-to-lymphocyte ratio with clinical outcomes in cancer immunotherapy: An evidence synthesis from 30 meta-analyses. Int. Immunopharmacol. 2024, 132, 111936. [Google Scholar] [CrossRef] [PubMed]
- Kuzuya, T.; Ishigami, M.; Ito, T.; Ishizu, Y.; Honda, T.; Ishikawa, T.; Hirooka, Y.; Fujishiro, M. Clinical characteristics and outcomes of candidates for second-line therapy, including regorafenib and ramucirumab, for advanced hepatocellular carcinoma after sorafenib treatment. Hepatol. Res. 2019, 49, 1054–1065. [Google Scholar] [CrossRef] [PubMed]
- Hiraoka, A.; Kumada, T.; Fukunishi, S.; Atsukawa, M.; Hirooka, M.; Tsuji, K.; Ishikawa, T.; Takaguchi, K.; Kariyama, K.; Itobayashi, E.; et al. Post-progression treatment eligibility of unresectable hepatocellular carcinoma patients treated with lenvatinib. Liver Cancer 2020, 9, 73–83. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Persano, M.; Rimini, M.; Tada, T.; Suda, G.; Shimose, S.; Kudo, M.; Cheon, J.; Finkelmeier, F.; Lim, H.Y.; Presa, J.; et al. Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients. Eur. J. Cancer 2023, 189, 112933. [Google Scholar] [CrossRef] [PubMed]
Patient Characteristics | n = 40 |
---|---|
Age, years; median (range) | 75 (40–91) |
Sex, male/female | 33/7 |
Etiology, HBV/HCV/non-viral | 6/9/25 |
Treatment line, 1st/2nd/3rd/4th/5th | 18/7/11/2/2 |
ECOG-PS, 0/1 | 33/7 |
Child–Pugh score, 5/6/7/8/9 | 20/13/5/1/1 |
mALBI grade, 1/2a/2b/3 | 12/9/19/1 |
BCLC stage, A/B/C | 1/22/17 |
Intrahepatic tumor number, <4/≥4 | 11/29 |
Maximum intrahepatic tumor size, <50 mm/≥50 mm | 26/14 |
Portal vein tumor thrombosis, 0/1/2/3/4 | 30/0/5/4/1 |
Extrahepatic metastasis, −/+ | 27/13 |
AFP level, ng/mL; median (range) | 108 (1.3–31,676) |
DCP level, mAU/mL; median (range) | 603 (10–162,000) |
AFP-L3 level, %; median (range) | 16.6 (<0.5–88.8) |
NLR; median (range) | 2.66 (1.03–10.95) |
Observation period, months; median (range) | 7.6 (1.5–16.0) |
CR n (%) | PR n (%) | SD n (%) | PD n (%) | NE n (%) | CRR | ORR | DCR | |
---|---|---|---|---|---|---|---|---|
8W-RECIST 1.1 | 0 (0) | 10 (25.0) | 13 (32.5) | 16 (40.0) | 1 (2.5) | 0% | 25.0% | 57.5% |
8W-mRECIST | 3 (7.5) | 9 (22.5) | 11 (27.5) | 16 (40.0) | 1 (2.5) | 7.5% | 30.0% | 57.5% |
8W-RECIST 1.1 | AFP Ratios, Median (SE) | p Value | |||||
---|---|---|---|---|---|---|---|
CR+PR (8W-OR) n = 8 | SD n = 7 | PD+NE (Non-8W-DC) n = 12 | CR+PR+SD (8W-DC) n = 15 | SD+PD+NE (Non-8W-OR) n = 19 | 8W-OR vs. Non-8W-OR | 8W-DC vs. Non-8W-DC | |
At 2W | 0.83 (0.26) | 0.85 (0.06) | 1.16 (0.13) | 0.84 (0.13) | 1.07 (0.10) | 0.3033 | 0.0127 |
At 4W | 0.39 (0.19) | 1.00 (0.13) | 1.22 (0.32) | 0.53 (0.12) | 1.08 (0.23) | 0.0068 | 0.0006 |
At 8W | 0.21 (0.25) | 0.89 (0.21) | 1.91 (0.92) | 0.88 (0.18) | 1.53 (0.61) | 0.0029 | 0.0015 |
8W-RECIST 1.1 | DCP Ratios, Median (SE) | p Value | |||||
---|---|---|---|---|---|---|---|
CR+PR (8W-OR) n = 10 | SD n = 11 | PD+NE (Non-8W-DC) n = 16 | CR+PR+SD (8W-DC) n = 21 | SD+PD+NE (Non-8W-OR) n = 27 | 8W-OR vs. Non-8W-OR | 8W-DC vs. Non-8W-DC | |
At 2W | 0.46 (0.23) | 1.21 (1.45) | 1.13 (0.34) | 0.86 (0.83) | 1.15 (0.61) | 0.0049 | 0.2057 |
At 4W | 0.15 (0.04) | 1.52 (0.43) | 1.23 (0.93) | 0.49 (0.29) | 1.46 (0.58) | <0.0001 | 0.0215 |
At 8W | 0.06 (0.06) | 1.26 (0.31) | 1.83 (1.51) | 0.50 (0.24) | 1.70 (0.94) | <0.0001 | 0.0032 |
8W-RECIST 1.1 | AFP-L3 Ratios, Median (SE) | p Value | |||||
---|---|---|---|---|---|---|---|
CR+PR (8W-OR) n = 9 | SD n = 11 | PD+NE (Non-8W-DC) n = 13 | CR+PR+SD (8W-DC) n = 20 | SD+PD+NE (Non-8W-OR) n = 24 | 8W-OR vs. Non-8W-OR | 8W-DC vs. Non-8W-DC | |
At 4W | 0.93 (0.15) | 1.01 (0.06) | 1.01 (0.08) | 1.00 (0.08) | 1.01 (0.05) | 0.3675 | 0.9388 |
At 8W | 1.00 (0.48) | 1.07 (0.09) | 1.06 (0.09) | 1.03 (0.21) | 1.06 (0.06) | 0.4188 | 0.6060 |
Factors | Univariate Analysis | Multivariate Analysis | ||
---|---|---|---|---|
HR (95%CI) | p Value | HR (95%CI) | p Value | |
Age (<75 years) | 0.841 (0.381–1.857) | 0.6685 | ||
Sex (female) | 1.588 (0.591–4.271) | 0.3594 | ||
Etiology (HBV or HCV) | 1.390 (0.619–3.117) | 0.4248 | ||
Treatment line (1st) | 0.404 (0.171–0.958) | 0.0395 | 0.374 (0.156–0.896) | 0.0274 |
ECOG-PS (0) | 0.536 (0.199–1.441) | 0.2164 | ||
Child–Pugh score (5) | 0.728 (0.330–1.606) | 0.4320 | ||
BCLC stage (A or B) | 0.642 (0.292–1.411) | 0.2697 | ||
Number of intrahepatic tumors (≥4) | 1.216 (0.452–3.269) | 0.6986 | ||
Maximum size of intrahepatic tumors (≥50 mm) | 0.851 (0.365–1.983) | 0.7088 | ||
Portal vein tumor thrombosis (+) | 1.466 (0.624–3.444) | 0.3804 | ||
Extrahepatic metastasis (+) | 0.528 (0.236–1.181) | 0.1200 | ||
AFP level (≥100 ng/mL) | 1.470 (0.660–3.277) | 0.3458 | ||
DCP level (≥400 mAU/mL) | 1.105 (0.502–2.432) | 0.8039 | ||
AFP-L3 level (≥10.0%) | 1.044 (0.458–2.380) | 0.9178 | ||
NLR (≤3.00) | 0.477 (0.211–2.347) | 0.0757 | 0.433 (0.188–0.996) | 0.0490 |
Adverse Event | Any Grade n (%) | Grade 1/2 n (%) | Grade 3/4 n (%) |
---|---|---|---|
Fever | 8 (20.0) | 8 (20.0) | 0 |
Diarrhea | 7 (17.5) | 2 (5.0) | 5 (12.5) |
Anorexia | 7 (17.5) | 6 (15.0) | 1 (2.5) |
General fatigue | 7 (17.5) | 7 (17.5) | 0 |
Pruritus | 7 (17.5) | 7 (17.5) | 0 |
Elevated aspartate aminotransferase | 3 (7.5) | 1 (2.5) | 2 (5.0) |
Skin rash | 3 (7.5) | 3 (7.5) | 0 |
Deterioration of liver function | 2 (5.0) | 0 | 2 (5.0) |
Reduced adrenal function | 1 (2.5) | 1 (2.5) | 0 |
Hypothyroidism | 1 (2.5) | 1 (2.5) | 0 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kuzuya, T.; Kawabe, N.; Muto, H.; Wada, Y.; Komura, G.; Nakano, T.; Tanaka, H.; Nakaoka, K.; Ohno, E.; Funasaka, K.; et al. Early Changes in Alpha-Fetoprotein and Des-γ-Carboxy Prothrombin Are Useful Predictors of Antitumor Response to Durvalumab Plus Tremelimumab Therapy for Advanced Hepatocellular Carcinoma. Curr. Oncol. 2024, 31, 4225-4240. https://doi.org/10.3390/curroncol31080315
Kuzuya T, Kawabe N, Muto H, Wada Y, Komura G, Nakano T, Tanaka H, Nakaoka K, Ohno E, Funasaka K, et al. Early Changes in Alpha-Fetoprotein and Des-γ-Carboxy Prothrombin Are Useful Predictors of Antitumor Response to Durvalumab Plus Tremelimumab Therapy for Advanced Hepatocellular Carcinoma. Current Oncology. 2024; 31(8):4225-4240. https://doi.org/10.3390/curroncol31080315
Chicago/Turabian StyleKuzuya, Teiji, Naoto Kawabe, Hisanori Muto, Yuryo Wada, Gakushi Komura, Takuji Nakano, Hiroyuki Tanaka, Kazunori Nakaoka, Eizaburo Ohno, Kohei Funasaka, and et al. 2024. "Early Changes in Alpha-Fetoprotein and Des-γ-Carboxy Prothrombin Are Useful Predictors of Antitumor Response to Durvalumab Plus Tremelimumab Therapy for Advanced Hepatocellular Carcinoma" Current Oncology 31, no. 8: 4225-4240. https://doi.org/10.3390/curroncol31080315
APA StyleKuzuya, T., Kawabe, N., Muto, H., Wada, Y., Komura, G., Nakano, T., Tanaka, H., Nakaoka, K., Ohno, E., Funasaka, K., Nagasaka, M., Miyahara, R., & Hirooka, Y. (2024). Early Changes in Alpha-Fetoprotein and Des-γ-Carboxy Prothrombin Are Useful Predictors of Antitumor Response to Durvalumab Plus Tremelimumab Therapy for Advanced Hepatocellular Carcinoma. Current Oncology, 31(8), 4225-4240. https://doi.org/10.3390/curroncol31080315